NPCE Logo

NeuroPace, Inc. (NPCE) 

NASDAQ
Market Cap
$268.93M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
631 of 774
Rank in Industry
79 of 99

Largest Insider Buys in Sector

NPCE Stock Price History Chart

NPCE Stock Performance

About NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was …

Insider Activity of NeuroPace, Inc.

Over the last 12 months, insiders at NeuroPace, Inc. have bought $0 and sold $11.47M worth of NeuroPace, Inc. stock.

On average, over the past 5 years, insiders at NeuroPace, Inc. have bought $8.57M and sold $3.86M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 62,398 shares for transaction amount of $93,535 was made by Accelmed Partners II L.P. (director) on 2022‑11‑22.

List of Insider Buy and Sell Transactions, NeuroPace, Inc.

2024-10-25Sale10 percent owner
223,991
0.697%
$5.45$1.22M0.00%
2024-10-23Sale10 percent owner
147
0.0005%
$6.02$8850.00%
2024-10-22Sale10 percent owner
4,082
0.0142%
$6.09$24,8530.00%
2024-10-21Sale10 percent owner
3,720
0.0125%
$6.10$22,679+17.42%
2024-10-18Sale10 percent owner
4,878
0.0162%
$6.29$30,692+11.44%
2024-10-17Sale10 percent owner
3,294
0.0111%
$6.28$20,686+11.74%
2024-10-16Sale10 percent owner
6,900
0.0231%
$6.57$45,336+9.24%
2024-10-15Sale10 percent owner
4,017
0.0133%
$6.50$26,098+7.28%
2024-10-14Sale10 percent owner
4,031
0.0134%
$6.54$26,360+3.87%
2024-10-11Sale10 percent owner
2,572
0.0083%
$6.35$16,320-1.82%
2024-10-10Sale10 percent owner
2,504
0.0078%
$6.12$15,317+5.47%
2024-10-09Sale10 percent owner
3,123
0.0097%
$6.10$19,065+6.22%
2024-10-08Sale10 percent owner
6,000
0.0196%
$6.43$38,552+0.93%
2024-10-07Sale10 percent owner
4,910
0.0167%
$6.66$32,687-3.14%
2024-10-04Sale10 percent owner
5,757
0.0203%
$6.92$39,830-5.12%
2024-10-03Sale10 percent owner
3,318
0.0118%
$6.97$23,115-6.62%
2024-10-02Sale10 percent owner
3,843
0.0135%
$6.87$26,401-5.48%
2024-10-01Sale10 percent owner
4,882
0.0168%
$6.77$33,051-3.92%
2024-09-30Sale10 percent owner
4,749
0.0163%
$6.73$31,961-4.66%
2024-09-27Sale10 percent owner
5,059
0.0171%
$6.63$33,5410.00%

Insider Historical Profitability

199.33%
ORBIMED ADVISORS LLC10 percent owner
3406335
11.4122%
$9.01114
Accelmed Partners II L.P.director
4432948
14.8517%
$9.0130+199.33%
Norton Evandirector
588235
1.9708%
$9.0110
Fischer Frank Mdirector
93291
0.3126%
$9.0110
Ridley IrinaGeneral Counsel and Secretary
61139
0.2048%
$9.0112

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
OrbiMed$52.85M13.924M0%+$00.41
Morgan Stanley$32.79M8.632.48M+0.95%+$307,124.40<0.01
Soleus Capital Management, L.P.$32.12M8.462.43M0%+$00.13
Nantahala Capital Management Llc$10.27M2.71778,260-33.69%-$5.22M0.48
Kent Lake Capital LLC$8.5M2.24643,629-4.07%-$360,584.413.84
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.